Categories
Change Password!
Reset Password!
The risk of anterior uveitis in patients with spondyloarthritis (SpA) or psoriatic arthritis (PsA) when treated with the soluble-receptor etanercept (ETA) or monoclonal antibodies (mAbs) has been investigated in this observational, retrolective study.
Around 25 to 40% of SpA patients are
expected to suffer from least one acute anterior uveitis episode. A
non-significant reduced risk of developing uveitis with soluble-receptor ETA
versus mAb treatment was found in this study on comparing qualitative and
quantitative analyses of the incidence of uveitis in a year after TNFi was used. Also, the TNFi should be
seletced based on the history of extra-articular symptoms of the patient.
The risk of anterior
uveitis in patients with spondyloarthritis (SpA) or psoriatic arthritis (PsA)
when treated with the soluble-receptor etanercept (ETA) or monoclonal
antibodies (mAbs) has been investigated in this observational, retrolective
study.
Between 2000- 2014, the patients with SpA
who were recommended anti-TNF agents were considered. The risk of uveitis was
interpreted qualitatively as number of
subjects with at least one uveitis and quantitatively as number of uveitis flares for each
individual. Adjustment of propensity score was done with respect to ETA or mAbs.
A total of 499 patients were included (302
had SpA and 127 had PsA). Out of these patients, 203 received a mAb and 226 ETA
as a 1st TNF-α inhibitor. Likelihood of uveitis occurring during the an year of
treatment decreased with ETA as compared to with mAbs however was not
significant following the adjustment for the propensity score. ETA had a
numerically higher over-time risk of uveitis as compared to with mAbs, but was
not statistically significant.
Uveitis risk in SpA patients does not
appear to be more with ETA than with mAb treatment. The occurrence of uveitis
in patients receiving an anti-TNF-α agent seems to be associated more with the
history of uveitis as compared to the treatment used.
Arthrtis Research & Therapy
Occurrence of anterior uveitis in patients with spondyloarthritis treated with tumor necrosis factor inhibitors: comparing the soluble receptor to monoclonal antibodies in a large observational cohort
Gisèle Khoury et al.
Comments (0)